Stada Arzneimittel AG claimed the number-one position in Russia’s consumer healthcare market as it kicked off the next phase of its investment in the country.
With its acquisition of a portfolio of OTC and Rx brands from Takeda Pharmaceutical Co. Ltd. now closed, Stada said it was positioned to “intensively expand its consumer health business in Russia
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?